Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E Health Claim Falls Short Of Significant Scientific Agreement - FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA has determined a health claim relating vitamin E to a reduced risk of heart disease does not meet the "significant scientific agreement" standard. The agency's decision is articulated in a Jan. 11 letter to the Washington, D.C. firm Emord & Associates, which submitted the claim petition on behalf of Julian Whitaker, MD, Durk Pearson, Sandy Shaw and others.

You may also be interested in...



Supplement Health Claim Approval Costs Unaffordable, Economist Says

Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.

Supplement Health Claim Approval Costs Unaffordable, Economist Says

Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.

Supplement Health Claim Approval Costs Unaffordable, Economist Says

Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel